EP2061493A4 - Compositions to reduce or prevent skin cancer - Google Patents

Compositions to reduce or prevent skin cancer

Info

Publication number
EP2061493A4
EP2061493A4 EP06789889A EP06789889A EP2061493A4 EP 2061493 A4 EP2061493 A4 EP 2061493A4 EP 06789889 A EP06789889 A EP 06789889A EP 06789889 A EP06789889 A EP 06789889A EP 2061493 A4 EP2061493 A4 EP 2061493A4
Authority
EP
European Patent Office
Prior art keywords
compositions
reduce
skin cancer
prevent skin
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06789889A
Other languages
German (de)
French (fr)
Other versions
EP2061493A1 (en
Inventor
Zoltan Kiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Essential SkinCare LLC
Original Assignee
Essential SkinCare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essential SkinCare LLC filed Critical Essential SkinCare LLC
Publication of EP2061493A1 publication Critical patent/EP2061493A1/en
Publication of EP2061493A4 publication Critical patent/EP2061493A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP06789889A 2006-08-21 2006-08-21 Compositions to reduce or prevent skin cancer Withdrawn EP2061493A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/032549 WO2008024103A1 (en) 2006-08-21 2006-08-21 Compositions to reduce or prevent skin cancer

Publications (2)

Publication Number Publication Date
EP2061493A1 EP2061493A1 (en) 2009-05-27
EP2061493A4 true EP2061493A4 (en) 2011-01-12

Family

ID=39107080

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06789889A Withdrawn EP2061493A4 (en) 2006-08-21 2006-08-21 Compositions to reduce or prevent skin cancer

Country Status (2)

Country Link
EP (1) EP2061493A4 (en)
WO (1) WO2008024103A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3345614A1 (en) * 2017-01-05 2018-07-11 Amrif B.V. Composition comprising alkaline phosphatase for use in the treatment of arthritides
WO2018175413A1 (en) 2017-03-21 2018-09-27 Synthetic Biologics, Inc. Alkaline phosphatase formulations
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302473A2 (en) * 1987-08-04 1989-02-08 Bristol-Myers Squibb Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US20020177583A1 (en) * 2001-03-29 2002-11-28 Zoltan Kiss Methods and compositions for the treatment of human and animal cancers
WO2007075199A1 (en) * 2005-12-28 2007-07-05 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374754B2 (en) * 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302473A2 (en) * 1987-08-04 1989-02-08 Bristol-Myers Squibb Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US20020177583A1 (en) * 2001-03-29 2002-11-28 Zoltan Kiss Methods and compositions for the treatment of human and animal cancers
WO2007075199A1 (en) * 2005-12-28 2007-07-05 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008024103A1 *

Also Published As

Publication number Publication date
WO2008024103A1 (en) 2008-02-28
EP2061493A1 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
HRP20160949T1 (en) Novel compositions and methods for cancer treatment
GB0719161D0 (en) Improvements relating to fabrick treatment compositions
AP2008004713A0 (en) Improvements relating to anti-parasetic compositions
EP2116224A4 (en) Cosmetic composition
EP1996612A4 (en) Compositions for treatment of cancer
PL2059223T3 (en) Skin care composition
EP2365815A4 (en) Extracellular matrix compositions for the treatment of cancer
ZA200905508B (en) Compositions and methods to prevent cancer with cupredoxins
GB0601644D0 (en) Antiperspirant compositions
IL197602A0 (en) Compositions and methods to prevent cancer with cupredoxins
PL2209458T3 (en) Skin treatment compositions
IL197235A0 (en) Therapeutic compositions
IL238394B (en) Compositions comprising combination of agents for cancer treatment
EP1986682A4 (en) Methods and compositions related to targeting tumors and wounds
GB0702931D0 (en) Skin application
EP1979487A4 (en) Cobalamin compositions for the treatment of cancer
HK1129601A1 (en) Compositions for contributing to the treatment of cancers
GB0908728D0 (en) Skin cleansing compositions
EP2061493A4 (en) Compositions to reduce or prevent skin cancer
EP2039340A4 (en) Skin cleansing composition
HK1138508A1 (en) Composition for external application to skin
GB0622847D0 (en) Cosmetic composition
EP2221040A4 (en) Composition for external application to skin
EP2056839A4 (en) Combination approaches to cancer treatment
HK1137331A1 (en) Composition for external application to skin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20101213

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20101207BHEP

Ipc: A61K 38/57 20060101ALI20101207BHEP

Ipc: A61K 38/46 20060101ALI20101207BHEP

Ipc: A61K 38/16 20060101AFI20080403BHEP

17Q First examination report despatched

Effective date: 20110830

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20130603